Aufklappen
Schliessen
Branche BiotechnologieAktienmarkt Sonstige |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| Do | Cantargia Phase I Clinical Results on the Antibody CAN04 Selected for Oral Presentation at ASCO | 2 | PR Newswire | |
| STOCKHOLM, April 18, 2019 /PRNewswire/ -- Cantargia AB today announce that the phase I clinical data generated by the antibody CAN04 will be presented orally at the 2019 Annual ASCO meeting... ► Artikel lesen | ||||
| 21.03. | Cantargia Makes a Directed Share Issue of Approximately SEK 106 Million for Increased Investments in the Clinical Development of CAN04 | 5 | PR Newswire | |
| STOCKHOLM, March 21, 2019 /PRNewswire/ -- The board of directors of Cantargia AB (publ) has resolved, pursuant to the general meeting's authorization, on a directed share issue of approximately... ► Artikel lesen | ||||
| CANTARGIA Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten! | LYNX | |||
► Artikel lesen | ||||
| 08.03. | Cantargia - Signs of growing interest in IL-1 pathway targets | 2 | Edison Investment Research | |
| Edison Investment Research - Pharmaceuticals & healthcare - Cantargia: In January 2019, the first patient was treated in the Phase IIa part of the Phase I/IIa CANFOUR study. Patient screening is ongoing... ► Artikel lesen | ||||
| 27.02. | Cantargia Publishes Year end Report for 2018 | 2 | PR Newswire | |
| STOCKHOLM, Feb. 27, 2019 /PRNewswire/ --Cantargia AB's ("Cantargia") year end report for 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant... ► Artikel lesen | ||||
| 25.01. | Cantargia: First Patient Treated With Antibody CAN04 in the Phase IIa Part of CANFOUR Trial | 5 | PR Newswire | |
| STOCKHOLM, Jan. 25, 2019 /PRNewswire/ --Cantargia AB (publ) today announce that the first patient in the phase IIa part of the CANFOUR clinical trial has received CAN04 (nidanilimab) treatment... ► Artikel lesen | ||||
| 03.01. | Cantargia - Nidanilimab transitioning to Phase IIa | 2 | Edison Investment Research | |
| Edison Investment Research - Pharmaceuticals & healthcare - Cantargia: On 7 December 2018 Cantargia reached an important milestone - the completion of the Phase I part of its Phase I/IIa CANFOUR study... ► Artikel lesen | ||||
| 10.12.18 | Cantargia Presents New Positive Preclinical Data on Antibody CAN04 at Major Antibody Conference | 4 | PR Newswire | |
| STOCKHOLM, Dec. 10, 2018 /PRNewswire/ --Cantargia AB (publ) today announce that new preclinical data on the antibody CAN04 (nidanilimab) will be presented at the scientific conference Antibody... ► Artikel lesen | ||||
| 07.12.18 | Cantargia: Phase I Safety Evaluation Part of CANFOUR Trial of Antibody CAN04 Completed and Phase IIa Part Being Initiated | 19 | PR Newswire | |
| STOCKHOLM, Dec 7, 2018 /PRNewswire/ -- Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation... ► Artikel lesen | ||||
| 15.11.18 | Cantargia Publishes Interim Report for Third Quarter of 2018 | 1 | PR Newswire | |
| STOCKHOLM, Nov. 15, 2018 /PRNewswire/ --
Cantargia AB's interim report for the third quarter of 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant... ► Artikel lesen | ||||
| 30.10.18 | Cantargia AB: Nomination Committee Appointed Ahead of 2019 Annual General Meeting | 31 | PR Newswire | |
| STOCKHOLM, Oct. 30, 2018 /PRNewswire/ -- Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2019 Annual General Meeting, and consists... ► Artikel lesen | ||||
| 20.10.18 | Cantargia Presented Positive Phase I Clinical Data with Lead Candidate CAN04 at ESMO | 36 | PR Newswire | |
| STOCKHOLM, Oct. 20, 2018 /PRNewswire/ -- The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose
Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease... ► Artikel lesen | ||||
| 09.10.18 | Cantargia Presents Clinical Data From its Ongoing CANFOUR Trial at ESMO | 50 | PR Newswire | |
| STOCKHOLM, Oct. 9, 2018 /PRNewswire/ -- Cantargia AB (publ) today announced that interim results from its clinical Phase I/II trial of lead candidate CAN04 (nidanilimab) will be presented... ► Artikel lesen | ||||
| 01.10.18 | Cantargia Obtains Patent in USA for the Antibody CAN03 | 4 | PR Newswire | |
| STOCKHOLM, Oct. 1, 2018 /PRNewswire/ -- Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has granted the company's patent application 15/501,710 directed... ► Artikel lesen | ||||
| 25.09.18 | Nasdaq Nordic: Nasdaq Stockholm Welcomes Cantargia to the Main Market | 3 | GlobeNewswire | |
| Stockholm, September 25, 2018 - Nasdaq (Nasdaq: NDAQ) announces that Cantargia
AB (short name: CANTA), a small cap company within the health care sector,
today will start trading of its shares on the... ► Artikel lesen | ||||
| 20.09.18 | Nasdaq Stockholm AB: Admission to trading of Cantargia AB (publ) on Nasdaq Stockholm (134/18) | 5 | GlobeNewswire | |
| On request of Cantargia AB (publ), company registration number 556791-6019,
Nasdaq Stockholm AB has admitted the company's shares to trading on Nasdaq
Stockholm, with effect from September 25, 2018.... ► Artikel lesen | ||||
| 20.09.18 | Nasdaq Stockholm AB: Last day of trading in Cantargia AB (publ) (341/18) | 4 | GlobeNewswire | |
| At the request of Cantargia AB (publ), the trading in the company's shares on
Nasdaq First North premier is to cease. As from September 25, 2018, the shares
will be listed on Nasdaq Stockholm.
The... ► Artikel lesen | ||||
| 19.09.18 | Cantargia Publishes Prospectus in Connection with the List Change to Nasdaq Stockholm's Main Market | 32 | PR Newswire | |
| STOCKHOLM, Sept. 19, 2018 /PRNewswire/ --
On 13 September 2018, Cantargia AB (publ) ("Cantargia" or the "Company") announced that Nasdaq Stockholm's Listing Committee had approved the... ► Artikel lesen | ||||
| 19.09.18 | Cantargia Obtains Patent Approval for the Antibody CAN04 (nidanilimab) in Japan | 3 | PR Newswire | |
| STOCKHOLM, Sweden, Sept. 19, 2018 /PRNewswire/ -- Cantargia AB announce that the Japanese patent authority, JPO has formally approved the company's patent application of the antibody CAN04... ► Artikel lesen | ||||
| 13.09.18 | Cantargia Has Been Approved for Listing on the Main Market of Nasdaq Stockholm | 3 | PR Newswire | |
| STOCKHOLM, Sept. 13, 2018 /PRNewswire/ --
Nasdaq Stockholm's Listing Committee has approved the admission of Cantargia AB's (publ) ("Cantargia" or the "Company") shares for trading on... ► Artikel lesen | ||||
| 21.08.18 | Cantargia Publishes Half Year Report | 3 | PR Newswire | |
| STOCKHOLM, Aug. 21, 2018 /PRNewswire/ -- Cantargia AB's half year report for the period January until June 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| EVOTEC | 21,80 | -1,98 % | Leerverkäufer-Alarm! Irre Bewegung bei SAF-Holland - markanter Aufbau bei Aixtron und Aurelius sowie Evotec und Wacker Chemie - deutlicher Abbau bei Software AG, Zalando und Siltronic sowie Heidelberger Druck, Osram und Leoni - insgesamt 18 Veränderungen! | |
| Hier finden Sie einen Überblick über die aktuellen Veränderungen bei den Leerverkaufspositionen deutscher Aktien am 16. April Seit geraumer Zeit sind die Aktien deutscher Unternehmen verstärkt ins Visier... ► Artikel lesen | ||||
| MORPHOSYS | 86,00 | -2,05 % | Morphosys: Neue Studie bei Erfolgsprojekt - Aktie mit Aufholjagd, Evotec im Visier | |
| Die Aktie von Morphosys hat in den vergangenen Wochen und Monaten nur durchschnittlich performt. Im 52-Wochenvergleich legte der Wert des Biotech-Unternehmens knapp sieben Prozent zu. Die Aktie von... ► Artikel lesen | ||||
| QIAGEN | 34,00 | -1,28 % | QIAGEN - Vor Erreichen des Ziels deutliche Kursabschläge | |
► Artikel lesen | ||||
| BB BIOTECH | 59,75 | -0,33 % | Münchener Rück, BB Biotech und Allianz: 3 starke Aktienrückkäufer! | |
| Wenn es um das Thema "Kapitalrückführungen" geht, scheiden sich oft die Geister. Viele Investoren neigen dazu, vor allem auf starke Dividendenausschütter zu setzen. Durch die regelmäßigen Ausschüttungen... ► Artikel lesen | ||||
| CLINUVEL | 14,70 | -6,55 % | Clinuvel Pharmaceuticals: Die große Rallye kommt erst noch? | |
| Die Aktie von Clinuvel Pharmaceuticals (WKN: A0JEGY) ist ein Paradebeispiel für Biotech- und Pharmaaktien, die Anlegern fantastische Gewinne bescheren und auch dafür, wie schnell Aktien aus diesem Sektor... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage